U.S. natural gas prices upside likely in 2026 - Morgan Stanley
SAN DIEGO - Arcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ:ARCT), a messenger RNA (mRNA) medicines company, has received a "Study Can Proceed" notification from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, ARCT-2304. This development allows the company to begin a clinical trial for its self-amplifying mRNA (sa-mRNA) vaccine candidate aimed at preventing H5N1 pandemic influenza.
The upcoming Phase 1 clinical trial, supported by the Biomedical Advanced Research and Development Authority (BARDA), is set to enroll around 200 healthy adults across the United States. Joseph Payne, President & CEO of Arcturus, stated that the trial will assess the safety, reactogenicity, and immunogenicity of ARCT-2304.
ARCT-2304 is formulated within a lipid nanoparticle and designed to create multiple copies of mRNA within the host cell after injection. This process is expected to achieve enhanced expression of antigens with potentially lower doses than conventional mRNA vaccines. The vaccine candidate also offers advantages in manufacturing speed compared to traditional egg- and cell-based vaccines and has a lyophilized formulation that is stable in refrigerators, simplifying storage and distribution.
Arcturus has been recognized for developing KOSTAIVE®, the world's first approved sa-mRNA COVID vaccine. Their pipeline includes treatments for various diseases, including ornithine transcarbamylase deficiency and cystic fibrosis, as well as partnered mRNA vaccine programs for COVID-19 and influenza.
The company's statement also contains forward-looking information about the potential success of ARCT-2304 and its alignment with U.S. government pandemic preparedness goals. However, these statements are subject to risks and uncertainties that could affect the actual results of the vaccine's development.
This announcement is based on a press release statement from Arcturus Therapeutics.
In other recent news, Arcturus Therapeutics has presented its third-quarter earnings report for 2024, revealing a net loss of $6.9 million, an improvement from the previous year, with revenues totaling $41.7 million. This report was accompanied by an announcement of a successful product launch in Japan, KOSTAIVE, which brought in a $25 million milestone payment. Canaccord Genuity, in response to these developments, has maintained a Buy rating on Arcturus shares and increased its price target to $74 from $72, citing the company's robust cash balance and the potential for 2025 to be transformative.
In the pipeline, Arcturus has confirmed the timing for the next update on ARCT-032 for cystic fibrosis, expected in the first half of 2025. However, there has been a minor delay in the ARCT-810 update for Ornithine Transcarbamylase (OTC) deficiency, now scheduled for the first half of 2025. Moreover, the approval of Kostaive in the European Union is now expected in the fourth quarter of 2024.
These recent developments have set the stage for substantial progress in 2025, with the anticipation of recording its first commercial revenue from Kostaive, securing EU approval for the product, and announcing progress in both the cystic fibrosis program and ARCT-810 in OTC. Arcturus also plans to file a Biologics License Application (BLA) for KOSTAIVE in the U.S. in H1 2025. These are some of the recent developments in the company.
InvestingPro Insights
As Arcturus Therapeutics (NASDAQ:ARCT) advances its mRNA vaccine technology with the FDA's green light for ARCT-2304, investors might be keen to understand the company's financial position and market performance. According to InvestingPro data, Arcturus has a market capitalization of $550.42 million, reflecting its position in the biotech sector.
The company's innovative approach to vaccine development is particularly noteworthy given its recent financial performance. InvestingPro data shows that Arcturus's revenue for the last twelve months as of Q3 2023 stood at $160.4 million, although it experienced a revenue decline of 45.85% during this period. This decline may be attributed to the cyclical nature of vaccine demand and development cycles.
Despite the revenue challenges, Arcturus maintains a strong financial foundation. An InvestingPro Tip highlights that the company "holds more cash than debt on its balance sheet," which is crucial for biotech firms investing heavily in research and development. This solid cash position could provide Arcturus with the financial flexibility needed to support its clinical trials and ongoing vaccine development efforts.
Another relevant InvestingPro Tip notes that Arcturus has seen a "significant return over the last week," with a 10.13% price total return. This recent uptick could be indicative of positive market sentiment following the FDA's decision on ARCT-2304.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights, with 11 more tips available for Arcturus Therapeutics. These tips could provide valuable context for understanding the company's potential in the competitive mRNA vaccine market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.